Therefore, for patients with clinically highly suspected CML, it is necessary to screen for atypical BCR::ABL fusion genes in patients negative for common BCR::ABL fusion variants to gain a better understanding of the treatment of rare BCR::ABL fusion variants. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.